1.Effects of different drying methods on content of main chemical compounds in Callicarpae Nudiflorae Folium.
Xiao-Yan HOU ; Xiao-Yan LAN ; Li-Wan ZHU ; Zi-Dong QIU ; Xiang LI ; Li ZHOU ; Zhi-Lai ZHAN ; Sheng HUANG ; Li-Ping KANG
China Journal of Chinese Materia Medica 2024;49(23):6320-6330
This study aims to identify the main chemical compounds, investigate the effects of different drying methods on the quality, and determine the appropriate drying method of Callicarpae Nudiflorae Folium. UPLC-UV-Q-TOF-MS was employed to characterize and identify 35 main compounds, including phenylethanoid glycosides, flavonoids, and iridoids in Callicarpae Nudiflorae Folium. A method for the simultaneous determination of 8 compounds with strong UV absorption and high content was established to evaluate the quality of Callicarpae Nudiflorae Folium dried by different methods. UPLC-UV-Q-TOF-MS combined with principal component analysis(PCA) was employed to compare the Callicarpae Nudiflorae Folium samples treated by microwave drying at different power(119, 231, and 385 W), drying in the shade, sun drying, and oven drying at different temperatures(50, 60, 70, 80, 90, and 100 ℃). The total content of decaffeoyl acteoside, picroside Ⅲ, galuteolin, forsythin B, acteoside, isoacteoside, 6-hydroxyluteolin-7-glucoside, and caffeic acid in Callicarpae Nudiflorae Folium, as well as the content of most compounds, decreased with the rise in drying temperature and with the decrease in microwave power. Considering the content of compounds, low carbon, and energy saving, microwave drying at 231 W, low-temperature drying, or natural drying is recommended for the production of Callicarpae Nudiflorae Folium. This study provides a scientific basis for the selection of drying methods for Callicarpae Nudiflorae Folium at the place of origin and for the improvement of quality standards.
Desiccation/methods*
;
Drugs, Chinese Herbal/chemistry*
;
Callicarpa/chemistry*
;
Plant Leaves/chemistry*
;
Chromatography, High Pressure Liquid
;
Flavonoids/analysis*
;
Microwaves
;
Mass Spectrometry
2.Effect of High-Concentration Uric Acid on Nitric Oxide.
Si-Yu QIN ; Rong-Yu LAN ; Jia ZENG ; Xue BAI ; Jing-Tao WANG ; Xiang-Lin YIN ; Rui-Jie QU ; Ming-Hai QU ; Hao JIANG ; Wen-Long LI ; Si-Ying PEI ; Zhi-Ling HOU ; Bao-Sheng GUAN ; Hong-Bin QIU
Acta Academiae Medicinae Sinicae 2023;45(4):666-671
Uric acid (UA) is the final product of purine metabolism in human body,and its metabolic disorder will induce hyperuricemia (HUA).The occurrence and development of HUA are associated with a variety of pathological mechanisms such as oxidative stress injury,activation of inflammatory cytokines,and activation of renin-angiotensin-aldosterone system.These mechanisms directly or indirectly affect the bioavailability of endogenous nitric oxide (NO).The decrease in NO bioavailability is common in the diseases with high concentration of UA as an independent risk factor.In this review,we summarize the mechanisms by which high concentrations of UA affect the endogenous NO bioavailability,with a focus on the mechanisms of high-concentration UA in decreasing the synthesis and/or increasing the consumption of NO.This review aims to provide references for alleviating the multisystem symptoms and improving the prognosis of HUA,and lay a theoretical foundation for in-depth study of the correlations between HUA and other metabolic diseases.
Humans
;
Nitric Oxide
;
Uric Acid
;
Hyperuricemia
;
Biological Availability
;
Cytokines
3.Association of Overlapped and Un-overlapped Comorbidities with COVID-19 Severity and Treatment Outcomes: A Retrospective Cohort Study from Nine Provinces in China.
Yan MA ; Dong Shan ZHU ; Ren Bo CHEN ; Nan Nan SHI ; Si Hong LIU ; Yi Pin FAN ; Gui Hui WU ; Pu Ye YANG ; Jiang Feng BAI ; Hong CHEN ; Li Ying CHEN ; Qiao FENG ; Tuan Mao GUO ; Yong HOU ; Gui Fen HU ; Xiao Mei HU ; Yun Hong HU ; Jin HUANG ; Qiu Hua HUANG ; Shao Zhen HUANG ; Liang JI ; Hai Hao JIN ; Xiao LEI ; Chun Yan LI ; Min Qing LI ; Qun Tang LI ; Xian Yong LI ; Hong De LIU ; Jin Ping LIU ; Zhang LIU ; Yu Ting MA ; Ya MAO ; Liu Fen MO ; Hui NA ; Jing Wei WANG ; Fang Li SONG ; Sheng SUN ; Dong Ting WANG ; Ming Xuan WANG ; Xiao Yan WANG ; Yin Zhen WANG ; Yu Dong WANG ; Wei WU ; Lan Ping WU ; Yan Hua XIAO ; Hai Jun XIE ; Hong Ming XU ; Shou Fang XU ; Rui Xia XUE ; Chun YANG ; Kai Jun YANG ; Sheng Li YUAN ; Gong Qi ZHANG ; Jin Bo ZHANG ; Lin Song ZHANG ; Shu Sen ZHAO ; Wan Ying ZHAO ; Kai ZHENG ; Ying Chun ZHOU ; Jun Teng ZHU ; Tian Qing ZHU ; Hua Min ZHANG ; Yan Ping WANG ; Yong Yan WANG
Biomedical and Environmental Sciences 2020;33(12):893-905
Objective:
Several COVID-19 patients have overlapping comorbidities. The independent role of each component contributing to the risk of COVID-19 is unknown, and how some non-cardiometabolic comorbidities affect the risk of COVID-19 remains unclear.
Methods:
A retrospective follow-up design was adopted. A total of 1,160 laboratory-confirmed patients were enrolled from nine provinces in China. Data on comorbidities were obtained from the patients' medical records. Multivariable logistic regression models were used to estimate the odds ratio (
Results:
Overall, 158 (13.6%) patients were diagnosed with severe illness and 32 (2.7%) had unfavorable outcomes. Hypertension (2.87, 1.30-6.32), type 2 diabetes (T2DM) (3.57, 2.32-5.49), cardiovascular disease (CVD) (3.78, 1.81-7.89), fatty liver disease (7.53, 1.96-28.96), hyperlipidemia (2.15, 1.26-3.67), other lung diseases (6.00, 3.01-11.96), and electrolyte imbalance (10.40, 3.00-26.10) were independently linked to increased odds of being severely ill. T2DM (6.07, 2.89-12.75), CVD (8.47, 6.03-11.89), and electrolyte imbalance (19.44, 11.47-32.96) were also strong predictors of unfavorable outcomes. Women with comorbidities were more likely to have severe disease on admission (5.46, 3.25-9.19), while men with comorbidities were more likely to have unfavorable treatment outcomes (6.58, 1.46-29.64) within two weeks.
Conclusion
Besides hypertension, diabetes, and CVD, fatty liver disease, hyperlipidemia, other lung diseases, and electrolyte imbalance were independent risk factors for COVID-19 severity and poor treatment outcome. Women with comorbidities were more likely to have severe disease, while men with comorbidities were more likely to have unfavorable treatment outcomes.
Adult
;
Aged
;
COVID-19/virology*
;
China/epidemiology*
;
Comorbidity
;
Female
;
Humans
;
Male
;
Middle Aged
;
Retrospective Studies
;
Severity of Illness Index
;
Treatment Outcome
4.Cardiac electrical and mechanical synchrony of super-responders to cardiac resynchronization therapy
Li KE-BEI ; Qian ZHI-YONG ; Qian XUE-SONG ; Zhou YONG ; Zhu DI-DI ; Qiu YUAN-HAO ; Wang YAO ; Hou XIAO-FENG ; Zou JIAN-GANG ; Sheng YU-FENG
Chinese Medical Journal 2020;133(2):141-147
Background:Super-responders (SRs) to cardiac resynchronization therapy (CRT) regain near-normal or normal cardiac function.The extent of cardiac synchrony of SRs and whether continuous biventricular (BIV) pacing is needed remain unknown.The aim of this study was to evaluate the cardiac electrical and mechanical synchrony of SRs.Methods:We retrospectively analyzed CRT recipients between 2008 and 2016 in 2 centers to identify SRs,whose left ventricular (LV) ejection fraction was increased to ≥50% at follow-up.Cardiac synchrony was evaluated in intrinsic and BIV-paced rhythms.Electrical synchrony was estimated by QRS duration and LV mechanical synchrony by single-photon emission computed tomography myocardial perfusion imaging.Results:Seventeen SRs were included with LV ejection fraction increased from 33.0 ± 4.6% to 59.3 ± 6.3%.The intrinsic QRS duration after super-response was 148.8 ± 30.0 ms,significantly shorter than baseline (174.8 ± 11.9 ms,P =0.004,t=-3.379) but longer than BIV-paced level (135.5 ± 16.7 ms,P =0.042,t =2.211).Intrinsic LV mechanical synchrony significantly improved after super-response (phase standard deviation [PSD],51.1 ± 16.5° vs.19.8 ± 8.1°,P < 0.001,t =5.726;phase histogram bandwidth (PHB),171.7±64.2° vs.60.5 ±22.9°,P< 0.001,t=5.376) but was inferior to BIV-paced synchrony (PSD,19.8 ± 8.1° vs.15.2 ± 6.4°,P =0.005,t =3.414;PHB,60.5 ± 22.9° vs.46.0 ± 16.3°,P =0.009,t =3.136).Condusions:SRs had significant improvements in cardiac electrical and LV mechanical synchrony.Since intrinsic synchrony of SRs was still inferior to BIV-paced rhythm,continued BIV pacing is needed to maintain longstanding and synchronized contraction.
5. Acute exacerbation of idiopathic pulmonary fibrosis: usual interstitial pneumonitis vs . possible usual interstitial pneumonitis pattern
Meng-Shu CAO ; Jian SHENG ; Tian-Zhen WANG ; Xiao-Hua QIU ; Dong-Mei WANG ; Yang WANG ; Yong-Long XIAO ; Hou-Rong CAI
Chinese Medical Journal 2019;132(18):2177-2184
Background:
The prognosis of acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is very poor with a high mortality. The aim of this study was to describe the clinical features and survival of patients with AE-IPF with usual pulmonary fibrosis (UIP) and possible UIP (P-UIP) pattern on chest high resolution computed tomography (HRCT).
Methods:
This retrospective study included 107 patients with AE-IPF admitted to Nanjing Drum Tower Hospital from January 2010 to December 2016. The subjects were divided into UIP (
6.Efficacy and Safety of Teriflunomide in Chinese Patients with Relapsing Forms of Multiple Sclerosis: A Subgroup Analysis of the Phase 3 TOWER Study.
Wei QIU ; De-Hui HUANG ; Shi-Fang HOU ; Mei-Ni ZHANG ; Tao JIN ; Hui-Qing DONG ; Hua PENG ; Chao-Dong ZHANG ; Gang ZHAO ; Yi-Ning HUANG ; Dong ZHOU ; Wei-Ping WU ; Bao-Jun WANG ; Ji-Mei LI ; Xing-Hu ZHANG ; Yan CHENG ; Hai-Feng LI ; Ling LI ; Chuan-Zhen LU ; Xu ZHANG ; Bi-Tao BU ; Wan-Li DONG ; Dong-Sheng FAN ; Xue-Qiang HU ; Xian-Hao XU ; TOWER Trial Chinese Group
Chinese Medical Journal 2018;131(23):2776-2784
Background:
Disease-modifying therapy is the standard treatment for patients with multiple sclerosis (MS) in remission. The primary objective of the current analysis was to assess the efficacy and safety of two teriflunomide doses (7 mg and 14 mg) in the subgroup of Chinese patients with relapsing MS included in the TOWER study.
Methods:
TOWER was a multicenter, multinational, randomized, double-blind, parallel-group (three groups), placebo-controlled study. This subgroup analysis includes 148 Chinese patients randomized to receive either teriflunomide 7 mg (n = 51), teriflunomide 14 mg (n = 43), or placebo (n = 54).
Results:
Of the 148 patients in the intent-to-treat population, adjusted annualized relapse rates were 0.63 (95% confidence interval [CI]: 0.44, 0.92) in the placebo group, 0.48 (95% CI: 0.33, 0.70) in the teriflunomide 7 mg group, and 0.18 (95% CI: 0.09, 0.36) in the teriflunomide 14 mg group; this corresponded to a significant relative risk reduction in the teriflunomide 14 mg group versus placebo (-71.2%, P = 0.0012). Teriflunomide 14 mg also tended to reduce 12-week confirmed disability worsening by 68.1% compared with placebo (hazard ratio: 0.319, P = 0.1194). There were no differences across all treatment groups in the proportion of patients with treatment-emergent adverse events (TEAEs; 72.2% in the placebo group, 74.5% in the teriflunomide 7 mg group, and 69.8% in the teriflunomide 14 mg group); corresponding proportions for serious adverse events were 11.1%, 3.9%, and 11.6%, respectively. The most frequently reported TEAEs with teriflunomide versus placebo were neutropenia, increased alanine aminotransferase, and hair thinning.
Conclusions:
Teriflunomide was as effective and safe in the Chinese subpopulation as it was in the overall population of patients in the TOWER trial. Teriflunomide has the potential to meet unmet medical needs for MS patients in China.
Trial Registration
ClinicalTrials.gov, NCT00751881; https://clinicaltrials.gov/ct2/show/NCT00751881?term=NCT00751881&rank=1.
China
;
Crotonates
;
administration & dosage
;
adverse effects
;
therapeutic use
;
Double-Blind Method
;
Drug Administration Schedule
;
Humans
;
Immunosuppressive Agents
;
administration & dosage
;
adverse effects
;
therapeutic use
;
Multicenter Studies as Topic
;
Multiple Sclerosis
;
drug therapy
;
metabolism
;
Proportional Hazards Models
;
Toluidines
;
administration & dosage
;
adverse effects
;
therapeutic use
7.Relationship between arsenic (+3 oxidation state) methyltransferase genetic polymorphisms and susceptibility to endemic arsenism
Wen-sheng, HOU ; Li-fang, ZHANG ; Qiu-ling, PEI
Chinese Journal of Endemiology 2013;(1):33-37
Objective To investigate the association between arsenic(+3 oxidation state) methyltransferase (AS3MT) genetic polymorphism and susceptibility to endemic arsenism.Methods Polymerase chain reactionrestriction fragment length polymorphism-single strand conformation polymorphism(PCR-RFLP-SSCP) technology was performed to detect mutations of AS3MT gene intron 8 and exon 9 in genome DNA of the 79 cases and 110 controls.PCR products with abnormal band forms were further sequenced to find the types and sites of mutation.Chi-square test and multivariate Logistic analyses were conducted.Results The incidence of the 9149 base mutation(A→C) in AS3MT gene intron 8(AS3MT-9149) in case group(19.0%,15/79) was lower than that in control group (23.6%,26/110).The incidence of the codon 287 mutation(ATG→AT/CG) in AS3MT gene exon 9(AS3MT-287)in case group(10.1%,8/79) was lower than that in control group (11.8%,13/110).However,statistical analysis indicated no significant difference in both mutations between two groups[AS3MT-9149:odds ratio(OR) =0.59,95% confidence interval(CI):0.26-1.31,P =0.195; AS3MT-287:OR =0.85,95% CI:0.32-230,P =0.751].Conclusions There are no significant association between the genetic polymorphisms of AS3MT-9149,AS3MT-287 and the susceptibility to endemic arsenism.Similarly,due to small sample amount,we can not exclude the possibility that these gene polymorphisms are related to susceptibility to endemic arsenism.
8.Prognostic power of abnormal cytogenetics for multiple myeloma: a multicenter study in China.
Yue-Yun LAI ; Xiao-Jun HUANG ; Zhen CAI ; Xiang-Shan CAO ; Fang-Ping CHEN ; Xie-Qun CHEN ; Bao-An CHEN ; Mei-Yun FANG ; Jia-Fu FENG ; Wei-Ling FU ; Hai-Ying GUO ; Ming HOU ; Jian HOU ; Yu HU ; Xiao-Tong HU ; Xiao-Mei HU ; Li-Qiang HUANG ; Jie JIN ; Jian-Yong LI ; Juan LI ; Wei LI ; Ying-Min LIANG ; Ting LIU ; Qi-Fa LIU ; Yan-Hui LIU ; Ping MAO ; Jian OUYANG ; Lu-Gui QIU ; Lin QIU ; Chun-Kui SHAO ; Bin SHI ; Yong-Ping SONG ; Zi-Min SUN ; Qi-Shan WANG ; Chun WANG ; Jian-Ming WANG ; Yun-Shan WANG ; Zhao WANG ; Jian-Bo WU ; Yin-Xia WU ; Rui-Xiang XIA ; Yong-Quan XUE ; Bao-Zhen YANG ; Guang YANG ; Zheng-Lin YANG ; Li YU ; Zhong YUAN ; Sheng ZHANG ; Yin ZHANG ; Hong-Guo ZHAO ; Li ZHAO ; Dao-Bin ZHOU ; Shan-Hua ZOU ; Yun-Feng ZHU
Chinese Medical Journal 2012;125(15):2663-2670
BACKGROUNDChromosomal abnormalities have been shown to play an important prognostic role in multiple myeloma (MM). Interphase fluorescence in situ hybridization (i-FISH) has been much more effective to identify cytogenetic aberrations in MM than conventional cytogenetic technique (CC). To clearly determine the cytogenetic features of Chinese MM patients and identify their prognostic implications, we designed a multicenter study based on i-FISH including 672 patients from 52 hospitals in China.
METHODSAll 672 patients were systematically screened for the following genomic aberrations: del(13q), IgH rearrangement, del(p53) and 1q21 amplifications.
RESULTSThe analysis showed that the chromosomal changes were detected in 22.1% patients by CC and in 82.3% patients by i-FISH. The most common abnormalities by CC were chromosome 1 aberrations (48.4%), -13/13q- (37.6%), hyperdiploidy (36.6%), hypodiploidy (30.1%) and IgH rearrangements (23.7%). The most frequent abnormalities by FISH was del(13q), which was found in 60.4% patients, whereas IgH rearrangement, 1q21 amplification and p53 deletions were detected in 57.6%, 49.0% and 34.7% cases, respectively. By statistical analysis, -13/13q- by CC was associated with low level of platelet (P = 0.015), hyperdiploidy was associated with low level of serum albumin (P = 0.028), and IgH rearrangement by FISH was associated with high level of β2 microglobulin (P = 0.019). Moreover, 1q21 amplification and del(p53) by FISH conferred a high incidence of progressive disease (PD) after initial therapy. Metaphase detection of IgH rearrangements and chromosome 1 aberrations concurrently was associated with a short progression free survival (PFS) (P = 0.036). No significant prognostic implications of other cytogenetic abnormalities were found associated with overall survival and PFS.
CONCLUSIONSChinese MM patients had similar cytogenetic abnormalities compared with the previous reported studies. However, the prognostic significance of FISH aberrations were not clearly determined and further study is required.
Adult ; China ; Chromosome Aberrations ; Chromosomes, Human, Pair 1 ; genetics ; Cytogenetic Analysis ; Female ; Humans ; In Situ Hybridization, Fluorescence ; Karyotyping ; Male ; Middle Aged ; Multiple Myeloma ; genetics ; pathology
9.Current pattern of Chinese dialysis units: a cohort study in a representative sample of units.
Qiu-Gen ZHOU ; Jian-Ping JIANG ; Sheng-Jie WU ; Jian-Wei TIAN ; Jiang-Hua CHEN ; Xue-Qing YU ; Ping-Yan CHEN ; Chang-Lin MEI ; Fei XIONG ; Wei SHI ; Wei ZHOU ; Xu-Sheng LIU ; Shi-Ren SUN ; Di XIE ; Jun LIU ; Xin XU ; Fan-Fan HOU
Chinese Medical Journal 2012;125(19):3434-3439
BACKGROUNDUnderstanding the characteristics of Chinese dialysis patients and the current practice trends is the first step to evaluate the association between practice pattern and outcome in these populations. In the present study, we evaluated the status of medical treatment and characteristic features of chronic dialysis patients in China.
METHODSThrough a clustering sampling, we selected 9 centers from the largest dialysis facilities in 6 cities around China. All adult undergoing dialysis in the selected units were screened. A total of 2388 (1775 on hemodialysis (HD) and 613 on peritoneal dialysis (PD)) patients were finally enrolled. All data were collected at enrollment on the bases of review of medical records.
RESULTSIn this cohort, 1313 (55.0%) were male. The mean age was 54 years old. The median time for dialysis was 26 months (12 - 51 months). Seventy-five percent of patients were on HD and 25.0% on PD. Among PD patients, about 21% patients did not receive dialysis adequacy. For HD patients, about 14.0% of them did not achieve dialysis adequacy when the target of kt/V was set as 1.2. Only 44.7% of patients achieved blood pressure target of 140/90 mmHg. About 60% of patients did not reach the hemoglobin target of 110 g/L even though 85.0% of them were treated with erythropoietin. In addition, 48.5% of the patients had uncontrolled mineral metabolism revealed by the high calcium-phosphate product. Compared with HD patients, higher level of serum glucose, triglyceride, and total and low density lipoprotein cholesterol were more common in PD patients.
CONCLUSIONSThis observational study suggests that many Chinese dialysis patients did not achieve the therapeutic target, particularly in blood pressure control, anemia correction, and mineral balance. PD patients were more likely to suffer metabolic disturbance.
Adult ; Aged ; Anemia ; physiopathology ; Blood Pressure ; physiology ; Female ; Humans ; Male ; Middle Aged ; Peritoneal Dialysis ; Renal Dialysis
10.Safety and efficacy of polymer-free paclitaxel-eluting microporous stent in real-world practice: 1-year follow-up of the SERY-I registry.
Rui-Yan ZHANG ; Qi ZHANG ; Jin-Zhou ZHU ; Liang-Long CHEN ; Chen-Yun ZHANG ; Xu-Chen ZHOU ; Yong YUAN ; Zhi-Xiong ZHONG ; Lang LI ; Jian QIU ; Wei WANG ; Xi-Ming CHEN ; Zhi-Jian YANG ; Jin-Chuan YAN ; Shao-Liang CHEN ; Yu-Qing HOU ; Yan-Qing WU ; Hai-Ming LUO ; Jian-Ping QIU ; Li ZHU ; Yan WANG ; Guo-Sheng FU ; Jian-An WANG ; Kang-Hua MA ; Yue-Hui YIN ; Dai-Fu ZHANG ; Xue-Song HU ; Guo-Ying ZHU ; Wei-Feng SHEN ; null
Chinese Medical Journal 2011;124(21):3521-3526

Result Analysis
Print
Save
E-mail